Skip to main content
. 2022 Nov;14(11):4416–4426. doi: 10.21037/jtd-22-1292

Figure 1.

Figure 1

Kaplan-Meier estimates of survival in 105 patients receiving chemotherapy plus rh-endostatin, comparing extended use of rh-endostatin and nonextended use of rh-endostatin. (A) PFS curve; (B) OS curve. PFS, progression-free-survival; OS, overall survival.